Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor

Sabatolimab is a humanized monoclonal antibody (hIgG4, S228P) directed against human T-cell immunoglobulin domain and mucin domain-3 (TIM-3). Herein, we describe the development and characterization of sabatolimab. Sabatolimab was tested for binding to its target TIM-3 and blocking properties. The f...

Full description

Saved in:

Bibliographic Details
Published in:	Immunotherapy advances Vol. 2; no. 1; p. ltac019
Main Authors:	Schwartz, Stephanie, Patel, Nidhi, Longmire, Tyler, Jayaraman, Pushpa, Jiang, Xiaomo, Lu, Hongbo, Baker, Lisa, Velez, Janelle, Ramesh, Radha, Wavreille, Anne-Sophie, Verneret, Melanie, Fan, Hong, Hu, Tiancen, Xu, Fangmin, Taraszka, John, Pelletier, Marc, Miyashiro, Joy, Rinne, Mikael, Dranoff, Glenn, Sabatos-Peyton, Catherine, Cremasco, Viviana
Format:	Journal Article
Language:	English
Published:	England Oxford University Press 01-01-2022
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Sabatolimab is a humanized monoclonal antibody (hIgG4, S228P) directed against human T-cell immunoglobulin domain and mucin domain-3 (TIM-3). Herein, we describe the development and characterization of sabatolimab. Sabatolimab was tested for binding to its target TIM-3 and blocking properties. The functional effects of sabatolimab were tested in T-cell killing and myeloid cell cytokine assays. Antibody-mediated cell phagocytosis (ADCP) by sabatolimab was also assessed. Sabatolimab was shown to (i) enhance T-cell killing and inflammatory cytokine production by dendritic cells (DCs); (ii) facilitate the phagocytic uptake of TIM-3-expressing target cells; and (iii) block the interaction between TIM-3 and its ligands PtdSer/galectin-9. Taken together, our results support both direct anti-leukemic effects and immune-mediated modulation by sabatolimab, reinforcing the notion that sabatolimab represents a novel immunotherapy with immuno-myeloid activity, holding promise for the treatment of myeloid cell neoplasms.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally.
ISSN:	2732-4303 2732-4303
DOI:	10.1093/immadv/ltac019